White House: J & J pause won't have 'significant impact' on U.S. vaccination plans

White House: Johnson & Johnson pause won't have 'significant impact' The White House said Tuesday that the pause on the Johnson & Johnson vaccine won’t have a “significant impact” on its national vaccination effort as the Pfizer-BioNTech and Moderna vaccine supply Justine Coleman TheHill

The White House said Tuesday that the pause on the Johnson & Johnson vaccine won’t have a “significant impact” on its national vaccination effort as the Pfizer-BioNTech and Moderna vaccine supply remains steady.  

The White House’s reassurance comes after the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) the same day called to halt administration of Johnson & Johnson vaccinations in the U.S. due to rare cases of blood clots.

“This announcement will not have a significant impact on our vaccination plan: Johnson & Johnson vaccine makes up less than 5 percent of the recorded shots in arms in the United States to date,”  the White House COVID-19 response coordinator, said in a statement. 

President Biden had previously secured enough doses of the Pfizer-BioNTech and Moderna vaccines for 300 million Americans, Zients said, adding that the U.S. had made more than 25 million doses of both vaccines available each week.

“This is more than enough supply to continue the current pace of vaccinations of 3 million shots per day, and meet the President’s goal of 200 million shots by his 100th day in office—and continue on to reach every adult who wants to be vaccinated,” he said.

“We are working now with our state and federal partners to get anyone scheduled for a J&J vaccine quickly rescheduled for a Pfizer or Moderna vaccine,” Zients added. ...